Butterfly Medical

What Butterfly Medical does

Butterfly Medical Ltd. is a privately held, venture-backed Israeli medical device company developing the Butterfly Prostatic Retraction Device, a minimally invasive implant for the treatment of benign prostatic hyperplasia (BPH). The device works by physically retracting the lateral lobes of the prostate to relieve urinary obstruction without cutting, burning, or puncturing tissue, distinguishing it from TURP, laser, Rezum, Urolift, and other ablative BPH procedures. It is designed as a long-term yet reversible implant that allows future urological intervention if needed, and the procedure can be performed under local anesthesia across hospital, ambulatory surgery center (ASC), and office-based urology clinic settings, supported by a simple learning curve for community urologists. The company is headquartered in Yokneam, Israel, with a small 1–10-person team and senior leadership drawn from Olympus, Coloplast, Abbott Vascular, and the Israeli medtech entrepreneurial ecosystem.

The Butterfly device is CE Mark approved and commercially available in the European Union and remains investigational in the United States, where the company is preparing a Pre-Market Approval (PMA) application supported by a completed 244-patient international pivotal trial whose 12-month follow-up was finalized in January 2026. Butterfly Medical's business model is hardware sales — a one-time sale of the implantable device to hospitals, ASCs, and urology clinics, with pricing that is not publicly disclosed and expected to be quote-based / contract-negotiated at the time of commercial launch. The planned U.S. go-to-market is a direct enterprise field-sales motion, anchored by CEO Patrick MacCarthy's prior U.S. BPH treatment launch at Olympus, and supported by board member Steffen Hovard's prior role as President of Interventional Urology at Coloplast. As of May 2026, the company had raised approximately $30 million in equity across multiple funding rounds, most recently a $21 million oversubscribed Series C led by participation from the European Innovation Council, Junson Capital, MedVenture, and New Rhein Healthcare Investors, alongside a non-dilutive €2.5 million EIC grant.

Name

Butterfly Medical

Legal name

Butterfly Medical Ltd.

Website

http://www.butterfly-medical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Butterfly Medical Ltd. is an Israeli medical device company developing the Butterfly Prostatic Retraction Device, a minimally invasive, reversible, tissue-sparing implant for benign prostatic hyperplasia (BPH). CE Mark approved in Europe and pursuing FDA PMA in the U.S.

Ownership category

akta.pro rank

Headquarters

HQ city

Yoqne`am `illit

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel, Infrastructure

Revenue model

1. Sale of implantable prostatic retraction device: Primary revenue stream is one-time sale of the Butterfly Prostatic Retraction Device to hospitals, ambulatory surgery centers (ASCs), and urology clinics. The device is CE Mark approved in Europe (commercially available) and investigational in the U.S. (limited by federal law to investigational use) pending FDA Pre-Market Approval, meaning U.S. revenue is contingent on regulatory clearance and a future commercial launch.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Butterfly Medical develops the Butterfly Prostatic Retraction Device, an implantable medical device that treats benign prostatic hyperplasia (BPH) by physically retracting the lateral lobes of the prostate without cutting, burning, or puncturing tissue. The device is fully reversible, designed as a long-term implant that still permits future urological intervention, and can be deployed under local anesthesia across clinic, ASC, and hospital settings. The product is CE Mark approved for commercial sale in Europe and investigational in the United States pending FDA Pre-Market Approval.

Product overview

Butterfly Medical's offering is a single, unified core product — the Butterfly Prostatic Retraction Device — rather than a platform-plus-modules architecture. It is a new-generation, minimally invasive implantable medical device for Benign Prostatic Hyperplasia (BPH) treatment that retracts prostatic lateral lobes without cutting, burning, or puncturing tissue. The device holds CE Mark approval in Europe, is investigational in the U.S. pending FDA Pre-Market Approval (PMA), and is supported by a 244-patient international pivotal clinical study whose 12-month follow-up was completed in January 2026 to support the planned PMA filing.

Differentiator

Problem solved

Functional benefit

Brands

• Butterfly Prostatic Retraction Device: The company's flagship CE-marked implantable device for minimally invasive treatment of benign prostatic hyperplasia (BPH).

Products and services

• Butterfly Prostatic Retraction Device An innovative, minimally invasive implantable device for the treatment of Benign Prostatic Hyperplasia (BPH) that retracts the lateral lobes of the prostate without cutting, burning, or puncturing tissue. Designed to be long-term yet reversible and allow future intervention if needed. The procedure is non-surgical, simple to learn, can be performed under local anesthesia, and is applicable across clinic, ambulatory surgery center (ASC), and hospital settings. Sold to hospitals, ASCs, and office-based urology clinics. Holds CE Mark in Europe and is investigational in the U.S. pending FDA PMA.

Quantifiable outcome

• 244 patients completed the international pivotal trial with 12-month follow-up completed in January 2026, supporting the planned FDA PMA submission.
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• ProVerum: ProVerum is developing a minimally invasive implant-based BPH therapy that mechanically reshapes the prostatic urethra. Its mechanism, target patient population, and care-setting strategy closely parallel Butterfly's, making it a relevant emerging peer.
• Zenflow: Zenflow is developing the Spring System, a minimally invasive nitinol implant for BPH designed to be delivered in an office setting under local anesthesia. Its office-based, low-anesthesia positioning closely mirrors Butterfly's clinic/ASC value proposition.
• SRS Medical: SRS Medical has developed urological device platforms including BPH-related technologies. It is an adjacent emerging player in the office-based urology device space where Butterfly is positioning its simple, local-anesthesia procedure.

Direct peers

• Medifocus: Medifocus has historically commercialized the Prolieve thermodilatation system, a minimally invasive office-based BPH treatment. It is a smaller-scale but directly comparable office-based BPH modality and a relevant prior-art reference for Butterfly's outpatient positioning.
• PROCEPT BioRobotics: PROCEPT BioRobotics markets Aquablation/Hydros, an FDA-cleared robotic waterjet ablation system for BPH. It competes head-to-head with Butterfly in the minimally invasive surgical BPH space, particularly in larger prostates and hospital/ASC settings.
• Laborie / Urotronic (Optilume BPH): Laborie (via Urotronic) is developing the Optilume BPH system, a drug-coated balloon dilation technology for BPH. It is a direct emerging competitor in the minimally invasive BPH category targeting the same urologist base.
• Teleflex (NeoTract / Urolift): Teleflex acquired NeoTract and markets the Urolift System, the leading FDA-approved minimally invasive implant for BPH that lifts and holds enlarged prostate tissue. Urolift is the closest direct mechanistic and clinical competitor to Butterfly's lateral-lobe retraction implant, competing for the same urology channel and the same patient population.

Broad incumbents

• Coloplast: Coloplast is a global urology and continence care incumbent whose Interventional Urology business is the largest commercial urology platform relevant to Butterfly. Board member Steffen Hovard was previously President of this division, and Coloplast's urology sales force defines the channel Butterfly will ultimately need to access or partner around.
• Boston Scientific (Rezum / NxThera): Boston Scientific acquired NxThera and markets Rezum, a minimally invasive water-vapor thermal therapy for BPH. Rezum is one of the established non-surgical BPH alternatives against which Butterfly will compete for urologist adoption and reimbursement.
• Olympus (iTind): Olympus acquired iTind, a temporarily implanted nitinol device for BPH that is later removed. iTind is a directly comparable temporary-implant BPH modality, and Olympus is also Butterfly CEO Patrick MacCarthy's former employer, making it both a competitor and a relevant reference point for Butterfly's commercial playbook.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=JX_HDYBEibQ
• LinkedInlinkedin.com/feed/update/urn:li:activity:7077651723946704897

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Butterfly Medical